BR112021018611A2 - Anticorpos tendo especificidade para btn2 e usos dos mesmos - Google Patents

Anticorpos tendo especificidade para btn2 e usos dos mesmos

Info

Publication number
BR112021018611A2
BR112021018611A2 BR112021018611A BR112021018611A BR112021018611A2 BR 112021018611 A2 BR112021018611 A2 BR 112021018611A2 BR 112021018611 A BR112021018611 A BR 112021018611A BR 112021018611 A BR112021018611 A BR 112021018611A BR 112021018611 A2 BR112021018611 A2 BR 112021018611A2
Authority
BR
Brazil
Prior art keywords
specificity
antibodies
btn2
btn2a
cancer
Prior art date
Application number
BR112021018611A
Other languages
English (en)
Inventor
Foucher Etienne
Cano Carla
Suong Le Kieu
Pasero Christine
Olive Daniel
Original Assignee
Imcheck Therapeutics Sas
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Inst Jean Paoli & Irene Calmettes
Univ Aix Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcheck Therapeutics Sas, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Inst Jean Paoli & Irene Calmettes, Univ Aix Marseille filed Critical Imcheck Therapeutics Sas
Publication of BR112021018611A2 publication Critical patent/BR112021018611A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

ANTICORPOS TENDO ESPECIFICIDADE PARA BTN2 E USOS DOS MESMOS. A presente invenção se refere a anticorpos tendo especificidade para BTN2A e usos dos mesmos, em particular para o tratamento de câncer.
BR112021018611A 2019-03-20 2020-03-20 Anticorpos tendo especificidade para btn2 e usos dos mesmos BR112021018611A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305345 2019-03-20
EP19219691 2019-12-24
PCT/EP2020/057794 WO2020188086A1 (en) 2019-03-20 2020-03-20 Antibodies having specificity for btn2 and uses thereof

Publications (1)

Publication Number Publication Date
BR112021018611A2 true BR112021018611A2 (pt) 2021-11-23

Family

ID=69810881

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018611A BR112021018611A2 (pt) 2019-03-20 2020-03-20 Anticorpos tendo especificidade para btn2 e usos dos mesmos

Country Status (12)

Country Link
US (1) US20220162305A1 (pt)
EP (1) EP3941940A1 (pt)
JP (1) JP2022525937A (pt)
KR (1) KR20220007041A (pt)
CN (1) CN113811545A (pt)
AU (1) AU2020243076A1 (pt)
BR (1) BR112021018611A2 (pt)
CA (1) CA3134122A1 (pt)
IL (1) IL286486A (pt)
MX (1) MX2021011334A (pt)
SG (1) SG11202109932WA (pt)
WO (1) WO2020188086A1 (pt)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU7071598A (en) 1997-04-10 1998-10-30 Erasmus University Rotterdam Diagnosis method and reagents
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2006116192A2 (en) * 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
EP3074040A4 (en) * 2013-11-29 2017-06-28 CSL Limited Method of treating cancer
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CA3013333A1 (en) * 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
JP7226833B2 (ja) 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用

Also Published As

Publication number Publication date
US20220162305A1 (en) 2022-05-26
KR20220007041A (ko) 2022-01-18
EP3941940A1 (en) 2022-01-26
CN113811545A (zh) 2021-12-17
SG11202109932WA (en) 2021-10-28
JP2022525937A (ja) 2022-05-20
WO2020188086A1 (en) 2020-09-24
AU2020243076A1 (en) 2021-10-14
MX2021011334A (es) 2021-12-10
CA3134122A1 (en) 2020-09-24
IL286486A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
EA201991214A1 (ru) Антитела против pd-1 и их композиции
GT201200318A (es) Anticuerpos hacia gdf8 humano
MX2020013468A (es) Anticuerpos il-11ra.
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
BR112016024363A2 (pt) conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
BR112022003956A2 (pt) Anticorpos anti-cd73
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
BR112016024619A2 (pt) conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer
EA201891628A1 (ru) Ингибирование аллергической реакции с использованием ингибитора il-33